New drug combination destroys bacterial infection that can be fatal to cystic fibrosis patients
The innovators worked with the Purdue Research Foundation Office of Technology Commercialization to patent the technology in the United States and in Europe. They are looking for partners. For more information, contact Dipak Narula of OTC at [email protected] and reference track code 2019-ROBI-68413.
"We are very excited about the acceptance of the intellectual property as this will enhance the possibility of finding commercial partners," Robinson said. "The potential for moving this to handheld, field deployable use is something we see in the future."
The group is evaluating the potential for fully portable use that would allow field use in virtually any environment.
The approach uses a high-powered laser pulse to obliterate a sample, while simultaneously collecting the spectral signature of the resultant emission. These signals are then compared with a database that translates the signals into an identification of the toxin or pathogen.
The work presented in this paper shows the proof of principle and is the basis for significant expansion of the studies. What makes the technology effective is the linking of antibodies to different heavy metal tags. This creates a unique fingerprint of atomic signatures that can be used to determine if any particular pathogen of interest in present in a sample. Source:
Purdue University Journal reference:
Gondhalekar, C., et al. (2020) Detection of E. coli labeled with metal-conjugated antibodies using lateral-flow assay and laser-induced breakdown spectroscopy. Analytical and Bioanalytical Chemistry . doi.org/10.1007/s00216-019-02347-3 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology